Moreover, C1M may serve as a pharmacodynamic marker, responding to therapies such as anti-IL6, anti-IL1, and anti-tumor necrosis factor (TNF) inhibitors, as well as JAK inhibitors in RA, PSA, and AS, and to anti-IL17 and anti-IL23 in PSA [67,68,69,70]. Here, TNF is linked to rheumatoid arthritis.